

INTRODUCTION	XXI
REASONS FOR THE STUDY	XXI
OBJECTIVES OF THE STUDY	XXI
AUDIENCE FOR THE STUDY.....	XXI
SCOPE AND CONTENT OF THE STUDY	XXI
METHODOLOGY USED IN STUDY.....	XXII
ANALYST CREDENTIALS.....	XXII
RELATED BCC REPORTS	XXII
MONTHLY NEWSLETTERS.....	XXIII
BCC ON-LINE SERVICES.....	XXIII
 SUMMARY.....	 XXIV
<i>SUMMARY TABLE POTENTIAL MARKET FOR ANTISENSE THERAPEUTICS,</i> <i>2007 (\$ BILLIONS).....</i>	 XXIV
<i>SUMMARY FIGURE DISTRIBUTION ANTISENSE THERAPEUTICS MARKET</i> <i>VALUE BY APPLICATION, 2007 (\$ MILLIONS).....</i>	 XXV
 ANTISENSE TECHNOLOGIES OVERVIEW	 1
GENE EXPRESSION	1
THE PROCESS OF GENE EXPRESSION	1
Step One: Signaling	1
<i>FIGURE 1 SIGNALING TO BEGIN EXPRESSION OF A GENE</i>	<i>1</i>
Step Two: Unwinding of DNA.....	1
<i>FIGURE 2 UNWINDING AND SEPARATION OF DNA STRANDS.....</i>	<i>2</i>
Step Three: Transcription	2
<i>FIGURE 3 RNA TRANSCRIPTION</i>	<i>2</i>
Step Four: RNA Processing.....	2
<i>FIGURE 4 RNA SPLICING.....</i>	<i>3</i>
Step Five: Translation	3
<i>FIGURE 5 TRANSLATION OF A PROTEIN.....</i>	<i>4</i>
HOW ANTISENSE CONTROLS GENE EXPRESSION	4
<i>FIGURE 6 HYBRIDIZATION OF ANTISENSE OLIGO TO MRNA</i>	<i>4</i>
BLOCKING OF MRNA SPLICING.....	4
<i>FIGURE 7 HYBRIDIZED OLIGO INTERFERES WITH SPLICING.....</i>	<i>5</i>
BLOCKING RIBOSOMES	5
<i>FIGURE 8 ANTISENSE OLIGO INHIBITION OF RIBOSOMES</i>	<i>5</i>
RNASE H CLEAVAGE OF MRNA.....	6
<i>FIGURE 9 RNASE H DIGESTION OF RNA-DNA DUPLEX.....</i>	<i>6</i>
CHEMISTRY OF ANTISENSE COMPOUNDS.....	6
THE ORIGINAL ANTISENSE COMPOUNDS	7
<i>FIGURE 10 STRUCTURE OF DNA AND RNA.....</i>	<i>7</i>
FIRST GENERATION ANTISENSE COMPOUNDS	7
<i>FIGURE 11 FIRST GENERATION OF ANTISENSE MOLECULES</i>	<i>8</i>
SECOND GENERATION ANTISENSE COMPOUNDS.....	8
<i>FIGURE 12 SECOND GENERATION ANTISENSE MODIFICATIONS</i>	<i>9</i>
2'-Ribose Modifications.....	9
N 3' to P 5' Modifications.....	9

Phosphorodiamidate Morpholino Modifications.....	9
Peptide Nucleic Acids (PNAs)	10
RIBOZYMES	10
<i>FIGURE 13 RIBOZYMES</i>	10
HAMMERHEAD RIBOZYMES	10
HAIRPIN RIBOZYMES	11
HISTORY OF ANTISENSE TECHNOLOGY.....	11
<i>FIGURE 14 NUMBER OF ANTISENSE SCIENTIFIC PUBLICATIONS, 1973-2002</i>	12
ANTISENSE THERAPEUTICS APPLICATIONS	13
CANCER.....	13
BRAIN CANCER.....	13
BREAST CANCER.....	13
COLORECTAL CANCER	14
KIDNEY CANCER.....	14
LEUKEMIA	14
LUNG CANCER.....	15
LYMPHOMA	15
SKIN CANCER	15
MULTIPLE MYELOMA	16
OVARIAN CANCER	16
PANCREATIC CANCER	16
PROSTATE CANCER.....	17
OVERVIEW OF CURRENT CANCER TREATMENT STRATEGIES	17
ANTISENSE CANCER TREATMENT STRATEGIES	17
<i>TABLE 1 ANTISENSE PRODUCTS FOR TREATMENT OF CANCER</i>	18
CORONARY HEART DISEASE.....	18
RESTENOSIS.....	18
OVERVIEW OF CURRENT TREATMENTS	19
ANTISENSE TREATMENTS FOR RESTENOSIS	19
<i>TABLE 2 ANTISENSE PRODUCTS FOR TREATMENT OF RESTENOSIS</i>	20
DIABETES	20
TYPE 2 DIABETES.....	20
CURRENT TREATMENTS FOR TYPE 2 DIABETES	20
ANTISENSE TREATMENT FOR TYPE 2 DIABETES	20
<i>TABLE 3 ANTISENSE PRODUCTS FOR TREATMENT OF TYPE 2 DIABETES</i>	21
IMMUNOLOGICAL DISORDERS.....	21
ASTHMA.....	21
CROHN'S DISEASE AND ULCERATIVE COLITIS	21
MULTIPLE SCLEROSIS.....	21
PSORIASIS.....	22
RHEUMATOID ARTHRITIS.....	22
CURRENT TREATMENT FOR IMMUNOLOGICAL DISORDERS	22

ANTISENSE TREATMENTS FOR IMMUNOLOGICAL DISORDERS	23
TABLE 4 ANTISENSE PRODUCTS FOR TREATMENT OF IMMUNOLOGICAL DISORDERS	23
INFECTIOUS DISEASES	23
CYTOMEGALOVIRUS/RETINITIS	23
HEPATITIS B.....	24
HEPATITIS C.....	24
HUMAN IMMUNODEFICIENCY VIRUS.....	25
HUMAN PAPILLOMAVIRUS.....	25
CURRENT TREATMENT OF INFECTIOUS DISEASES.....	25
ANTISENSE TREATMENT FOR INFECTIOUS DISEASES.....	26
TABLE 5 ANTISENSE PRODUCTS FOR TREATMENT OF INFECTIOUS DISEASES.....	26
POLYCYSTIC KIDNEY DISEASE	26
POLYCYSTIC KIDNEY DISEASE	26
CURRENT TREATMENTS FOR POLYCYSTIC KIDNEY DISEASE.....	27
ANTISENSE TREATMENT FOR POLYCYSTIC KIDNEY DISEASE.....	27
RETINAL DISORDERS	27
AGE-RELATED MACULAR DEGENERATION.....	27
DIABETIC RETINOPATHY.....	28
PROLIFERATIVE VITREORETINOPATHY	28
CURRENT TREATMENTS FOR RETINA DISORDERS.....	28
ANTISENSE TREATMENT FOR RETINAL DISORDERS	29
TABLE 6 ANTISENSE PRODUCTS FOR TREATMENT OF RETINAL DISORDERS.....	29
ANTISENSE THERAPEUTICS PRODUCTS	30
AEGERA THERAPEUTICS INC.	30
ANTISENSE XIAP (X-LINKED INHIBITOR OF APOPTOSIS).....	30
Type of Antisense Technology	30
Stage of Development.....	30
ANGIOGENE INC.	30
OLIGLOW™	30
Type of Antisense Technology	31
Stage of Development.....	31
ANTISENSE PHARMA GMBH	31
AP 12009.....	31
Type of Antisense Technology	31
Stage of Development.....	32
ANTISENSE THERAPEUTICS LTD.	32
ATL 1101	32
Type of Antisense Technology	32
Stage of Development.....	32
ATL 1102	32

Type of Antisense Technology	33
Stage of Development	33
AVI BIOPHARMA	33
AVI 4014	33
Type of Antisense Technology	33
Stage of Development	33
AVI 4126	33
Type of Antisense Technology	34
Stage of Development	34
AVI 4557	34
Type of Antisense Technology	34
Stage of Development	34
ONCOMYC-NG	35
Type of Antisense Technology	35
Stage of Development	35
<i>TABLE 7 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC ONCOMYC</i>	35
RESTINE-NG	35
Type of Antisense Technology	36
Stage of Development	36
ENZO THERAPEUTICS	36
HGTV-43	36
Type of Antisense Technology	36
Stage of Development	36
EPIGENESIS PHARMACEUTICALS, INC.	37
DURASON™ (EPI-2010)	37
Type of Antisense Technology	37
Stage of Development	37
GENTA	37
GENASENSE™	37
Type of Antisense Technology	37
Stage of Development	38
<i>TABLE 8 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC</i>	
<i>GENASENSE™</i>	38
HYBRIDON, INC.	38
ANTISENSE EPIDERMAL GROWTH FACTOR RECEPTOR	38
Type of Antisense Technology	39
Stage of Development	39
ANTISENSE NUCLEOTIDE EXCISION REPAIR PROTEIN	
XPA	39
Type of Antisense Technology	39
Stage of Development	39
ANTISENSE SURVIVIN	39
Type of Antisense Technology	40
Stage of Development	40
GEM®92	40

Type of Antisense Technology	40
Stage of Development	40
GEM [®] 220	40
Type of Antisense Technology	41
Stage of Development	41
GEM [®] 231	41
Type of Antisense Technology	41
Stage of Development	41
<i>TABLE 9 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC GEM[®]231</i>	<i>41</i>
GEM [®] 240	42
Type of Antisense Technology	42
Stage of Development	42
IMMUSOL INC.	42
PROLIFERASE [™]	42
Type of Antisense Technology	42
Stage of Development	42
RESTENASE [™]	43
Type of Antisense Technology	43
Stage of Development	43
VITRENASE [™]	43
Type of Antisense Technology	43
Stage of Development	43
ISIS PHARMACEUTICALS	44
AFFINITAC [™] (ISIS 3521)	44
Type of Antisense Technology	44
Stage of Development	44
<i>TABLE 10 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC</i>	
<i>AFFINITAC[™]</i>	<i>45</i>
ALICAFORSEN (ISIS 2302)	45
Type of Antisense Technology	45
Stage of Development	45
<i>TABLE 11 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC</i>	
<i>ALICAFORSEN</i>	<i>45</i>
ISIS 2503	46
Type of Antisense Technology	46
Stage of Development	46
<i>TABLE 12 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC ISIS 2503</i>	<i>46</i>
ISIS 13650	47
Type of Antisense Technology	47
Stage of Development	47
ISIS 14803	47
Type of Antisense Technology	47
Stage of Development	47
ISIS 104838	48
Type of Antisense Technology	48

Stage of Development.....	48
<i>TABLE 13 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC ISIS 104828.....</i>	<i>48</i>
ISIS 113715	48
Type of Antisense Technology.....	48
Stage of Development.....	49
VITRAVENE™ (FOMIVIRSEN)	49
Type of Antisense Technology.....	49
Stage of Development.....	49
LORUS THERAPEUTICS.....	49
GTI 2040	49
Type of Antisense Technology.....	49
Stage of Development.....	50
<i>TABLE 14 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC GTI 2040.....</i>	<i>50</i>
GTI 2501	50
Type of Antisense Technology.....	50
Stage of Development.....	50
METHYLGENE	51
MG 98.....	51
Type of Antisense Technology.....	51
Stage of Development.....	51
NEOPHARM	51
LERAF-AON.....	51
Type of Antisense Technology.....	51
Stage of Development.....	52
ONCOGENEX THERAPEUTICS	52
OGX-011	52
Type of Antisense Technology.....	52
Stage of Development.....	52
<i>TABLE 15 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC OGX-011</i>	<i>52</i>
ORIGENIX TECHNOLOGIES.....	53
ORI-1001.....	53
Type of Antisense Technology.....	53
Stage of Development.....	53
PANACEA PHARMACEUTICALS	53
PAN 346.....	53
Type of Antisense Technology.....	53
Stage of Development.....	54
RIBOZYME PHARMACEUTICALS	54
ANGIOZYME®.....	54
Type of Antisense Technology.....	54
Stage of Development.....	54
<i>TABLE 16 CLINICAL TRIAL STATUS OF ANTISENSE THERAPEUTIC</i>	
ANGIOZYME®.....	<i>54</i>
HEPBZYME™	55
Type of Antisense Technology.....	55

Stage of Development.....	55
HEPTAZYME™.....	55
Type of Antisense Technology.....	55
Stage of Development.....	55
HERZYME™.....	55
Type of Antisense Technology.....	56
Stage of Development.....	56
MARKETS FOR ANTISENSE THERAPEUTICS APPLICATIONS	57
CANCER THERAPEUTICS	57
TABLE 17 <i>INCIDENCE OF CANCER IN THE U.S., THROUGH 2007 (NUMBER OF CASES)</i>	57
FIGURE 15 <i>INCIDENCE OF TYPES OF CANCERS, 2002, 2002 AND 2007 (NUMBER OF CASES)</i>	58
TABLE 18 <i>MARKET FOR CANCER THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS)</i>	59
TABLE 19 <i>COST OF CANCER THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR)</i>	59
RESTENOSIS THERAPEUTICS.....	59
TABLE 20 <i>STENTS USED IN ANGIOPLASTY PROCEDURES, THROUGH 2007 (MILLIONS OF UNITS)</i>	60
TABLE 21 <i>COST OF STENTS IN THE U.S., THROUGH 2007 (\$/STENT)</i>	60
TABLE 22 <i>MARKET FOR STENTS IN THE U.S., THROUGH 2007 (\$ BILLIONS)</i>	60
TYPE 2 DIABETES THERAPEUTICS.....	60
TABLE 23 <i>PREVALENCE OF TYPE 2 DIABETES, THROUGH 2007 (THOUSANDS OF CASES)</i>	61
TABLE 24 <i>COST OF TYPE 2 DIABETES THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR)</i>	61
TABLE 25 <i>MARKET FOR TYPE 2 DIABETES THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS)</i>	61
IMMUNOLOGICAL DISORDER THERAPEUTICS	62
TABLE 26 <i>PREVALENCE OF IMMUNOLOGICAL DISORDERS POTENTIAL TREATED WITH ANTISENSE THERAPEUTICS, THROUGH 2007 (THOUSAND CASES)</i>	62
FIGURE 16 <i>PREVALENCE OF IMMUNOLOGICAL DISORDERS, 2002, 2002 AND 2007 (THOUSAND CASES)</i>	63
TABLE 27 <i>MARKET FOR THERAPEUTICS FOR IMMUNOLOGICAL DISORDERS, THROUGH 2007 (\$ BILLIONS)</i>	63
ASTHMA.....	64
TABLE 28 <i>COST OF ASTHMA THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR)</i>	64
TABLE 29 <i>MARKET FOR ASTHMA THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS)</i>	64
CROHN'S DISEASE AND ULCERATIVE COLITIS	64
TABLE 30 <i>COST OF CROHN'S DISEASE AND ULCERATIVE COLITIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR)</i>	65
TABLE 31 <i>MARKET FOR CROHN'S DISEASE AND ULCERATIVE COLITIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS)</i>	65
MULTIPLE SCLEROSIS.....	65

TABLE 32 COST OF MULTIPLE SCLEROSIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	66
TABLE 33 MARKET FOR MULTIPLE SCLEROSIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	66
PSORIASIS.....	66
TABLE 34 COST OF PSORIASIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	67
TABLE 35 MARKET FOR PSORIASIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	67
RHEUMATOID ARTHRITIS.....	67
TABLE 36 COST OF RHEUMATOID ARTHRITIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	68
TABLE 37 MARKET FOR RHEUMATOID ARTHRITIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	68
INFECTIOUS DISEASE THERAPEUTICS.....	68
TABLE 38 PREVALENCE OF VIRAL DISEASES POTENTIALLY TREATED WITH ANTISENSE THERAPEUTICS, THROUGH 2007 (THOUSAND CASES).....	69
FIGURE 17 PREVALENCE OF VIRAL DISEASE, 2000, 2002 AND 2007 (THOUSAND CASES).....	69
TABLE 39 MARKET FOR INFECTIOUS DISEASE THERAPEUTICS, THROUGH 2007 (\$ BILLIONS).....	70
CYTOMEGALOVIRUS (CMV) RETINITIS.....	70
TABLE 40 COST OF CMV RETINITIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	71
TABLE 41 MARKET FOR CMV RETINITIS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ MILLIONS).....	71
HEPATITIS B VIRUS (HBV)	71
TABLE 42 COST OF HBV INFECTIONS AND CHRONIC DISEASE THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	72
TABLE 43 MARKET FOR HBV INFECTIONS AND CHRONIC DISEASE THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	72
HEPATITIS C VIRUS (HCV)	72
TABLE 44 COST OF HCV INFECTIONS AND CHRONIC DISEASE THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	73
TABLE 45 MARKET FOR HCV INFECTIONS AND CHRONIC DISEASE THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	73
HUMAN IMMUNODEFICIENCY VIRUS (HIV)	73
TABLE 46 COST OF HIV INFECTIONS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	74
TABLE 47 MARKET FOR HIV INFECTIONS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	74
HUMAN PAPILLOMAVIRUS (HPV).....	74
TABLE 48 COST OF HPV INFECTIONS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	75
TABLE 49 MARKET FOR HPV INFECTIONS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	75
POLYCYSTIC KIDNEY THERAPEUTICS.....	75
TABLE 50 PREVALENCE OF POLYCYSTIC KIDNEY DISEASE, THROUGH 2007 (NUMBER OF CASES).....	75
TABLE 51 COST OF POLYCYSTIC KIDNEY DISEASE THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	76

TABLE 52 MARKET FOR POLYCYSTIC KIDNEY DISEASE THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	76
RETINA DISORDERS THERAPEUTICS	76
TABLE 53 PREVALENCE OF RETINAL DISORDERS, THROUGH 2007 (THOUSAND CASES).....	77
FIGURE 18 PREVALENCE OF RETINAL DISORDERS, 2000-2007 (THOUSAND CASES).....	77
TABLE 54 MARKET FOR RETINAL DISORDERS THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	78
AGE-RELATED MACULAR DEGENERATION (AMD).....	78
TABLE 55 COST OF AGE-RELATED MACULAR DEGENERATION THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	78
TABLE 56 MARKET FOR AGE-RELATED MACULAR DEGENERATION THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	79
DIABETIC RETINOPATHY (DR)	79
TABLE 57 COST OF DIABETIC RETINOPATHY THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	79
TABLE 58 MARKET FOR DIABETIC RETINOPATHY THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	80
PROLIFERATIVE VITREORETINOPATHY (PVR)	80
TABLE 59 COST OF PROLIFERATIVE VITREORETINOPATHY THERAPEUTICS IN THE U.S., THROUGH 2007 (\$/PATIENT/YEAR).....	80
TABLE 60 MARKET FOR PROLIFERATIVE VITREORETINOPATHY THERAPEUTICS IN THE U.S., THROUGH 2007 (\$ BILLIONS).....	80
POTENTIAL MARKETS FOR ANTISENSE THERAPEUTICS.....	81
CANCER.....	82
TABLE 61 ANTISENSE CANCER THERAPEUTICS MARKET, 2007 (\$ MILLIONS).....	82
Cancer (Continued).....	83
RESTENOSIS.....	84
TABLE 62 ANTISENSE ANTI-RESTENOSIS THERAPEUTICS MARKET, 2007 (\$ MILLIONS)	84
TYPE 2 DIABETES.....	84
IMMUNOLOGICAL DISORDERS	84
TABLE 63 ANTISENSE IMMUNOLOGICAL DISORDER THERAPEUTICS MARKETS, 2007 (\$ MILLIONS).....	85
INFECTIOUS DISEASES	85
TABLE 64 ANTISENSE INFECTIOUS DISEASE THERAPEUTICS MARKET, 2007 (\$ MILLIONS)	86
POLYCYSTIC KIDNEY DISEASE	86
TABLE 65 ANTISENSE POLYCYSTIC KIDNEY DISEASE THERAPEUTICS MARKET, 2007 (\$ MILLIONS).....	87
RETINAL DISORDERS.....	87
TABLE 66 ANTISENSE RETINAL DISORDERS THERAPEUTICS MARKET, 2007 (\$ MILLIONS)	87
TOTAL POTENTIAL MARKET FOR ANTISENSE THERAPEUTICS.....	88
TABLE 67 POTENTIAL MARKET FOR ANTISENSE THERAPEUTICS, 2007 (\$ MILLIONS)	88
THE TECHNOLOGY BEHIND ANTISENSE PRODUCTS.....	89

NEW DEVELOPMENTS IN ANTISENSE TECHNOLOGY.....	89
THERAPEUTIC DISCOVERY, TARGET VALIDATION, AND GENE FUNCTION	89
TABLE 68 DEVELOPER OF DRUG DISCOVERY ANTISENSE APPLICATIONS	89
PATENTS.....	90
PATENT CATEGORIES.....	90
Chemistry.....	90
Drug Discovery	90
TABLE 69 U.S. ANTISENSE AND RELATED TECHNOLOGY PATENTS.....	91
Therapeutics	91
Other	91
ANTISENSE INDUSTRY STRUCTURE AND COMPLETIVE PROFILE	92
ANTISENSE INDUSTRY STRUCTURE.....	92
WORLDWIDE DISTRIBUTION OF ANTISENSE THERAPEUTICS DEVELOPERS	92
TABLE 70 COMPANIES DEVELOPING ANTISENSE PRODUCTS	92
TABLE 70 (CONTINUED).....	93
FIGURE 19 WORLDWIDE DISTRIBUTION OF DEVELOPERS OF ANTISENSE THERAPEUTICS, 2002 (%).....	93
APPLICATION OF ANTISENSE THERAPEUTICS	93
FIGURE 20 DISTRIBUTION OF ANTISENSE THERAPEUTICS BY APPLICATION, 2002 (%).....	94
TABLE 71 APPLICATIONS FOR ANTISENSE THERAPEUTICS.....	95
DEVELOPMENT AND REGULATORY ENVIRONMENT OF ANTISENSE THERAPEUTICS	95
DEVELOPMENT OF THERAPEUTIC AGENTS	95
TABLE 72 DEVELOPMENT STAGES OF THERAPEUTIC AGENTS.....	96
The Development of Therapeutic Agents	96
Research and Discovery.....	96
Preclinical Development.....	96
Phase I Clinical Trials	97
Phase II Clinical Trials.....	97
Phase III Clinical Trials	97
Approval Phase	98
ANTISENSE THERAPEUTIC DEVELOPMENT	98
FIGURE 21 DISTRIBUTION OF ANTISENSE PRODUCTS DEVELOPMENT STAGE (%).....	98
FIGURE 21 (CONTINUED)	99
TABLE 73 STAGE OF DEVELOPMENT OF ANTISENSE PRODUCTS.....	99
TABLE 73 (CONTINUED).....	100
STRATEGIC ALLIANCES AND PARTNERSHIP.....	100
ANGIOGENE INC.	100
Abbott Vascular	100
ANTISENSE PHARMA	100
Biagnostik GmbH	100
ANTISENSE THERAPEUTICS	100

Isis Pharmaceuticals	100
Murdoch Children’s Research Institute.....	101
AVI BIOPHARMA.....	101
Medtronic	101
Exelixis Inc.....	101
EPIGENESIS PHARMACEUTICAL.....	101
Taisho Pharmaceuticals	101
Chiesi Farmaceutici S.P.A.	101
Hybridon	101
GENTA	102
Aventis	102
HYBRIDON	102
Epigenesis Pharmaceuticals	102
MethylGene.....	102
Micrologix Biotech	102
OriGenix Technologies	102
IMMUSOL	103
Chugai Pharma USA LLC.....	103
Vertex Pharmaceuticals	103
Novartis.....	103
ISIS PHARMACEUTICALS	103
Abbott Laboratories.....	103
Amgen Inc.	103
Celera Genomic Group	103
Elan Partnerships.....	104
Novartis Ophthalmic	104
METHYLGENE INC.....	104
MGI Pharma	104
ONCOGENEX TECHNOLOGIES	104
Isis Pharmaceuticals	104
ORIGENIX TECHNOLOGY	105
RIBOZYME PHARMACEUTICALS	105
Archemix	105
STRATEGIES OF LEADING ANTISENSE COMPANIES	105
COMPANY PROFILES	106
AEGERA THERAPEUTICS INC.	106
ANGIOGENE INC.	106
ANTISENSE PHARMA GMBH	107
ANTISENSE THERAPEUTICS LTD.	107
ATUGEN AG	108
AVI BIOPHARMA	109
BENITEC AUSTRALIA LIMITED	109
BIOGNOSTIK GMBH.....	110
ENZO THERAPEUTICS	110

EPIGENESIS PHARMACEUTICALS	111
EXEGENICS INC.	111
GENTA INC.	112
HYBRIDON INC.	112
IMMUSOL INC.	113
INEX PHARMACEUTICAL CORP.	113
ISIS PHARMACEUTICALS	114
LORUS THERAPEUTICS INC.	115
METHYLGENE INC.	116
MICROLOGIX BIOTECH INC.	116
NEOPHARM INC.	117
ONCOGENEX TECHNOLOGIES.....	117
ORIGENIX TECHNOLOGIES.....	118
PANACEA PHARMACEUTICALS	118
PATHECO A/S	119
RIBOZYME PHARMACEUTICALS INC.	119
SEQUITUR INC.....	120
SALUS THERAPEUTICS	120
SALUS THERAPEUTICS (CONTINUED)	121
APPENDIX A COMPANY BY TYPE OF ANTISENSE PRODUCT	122
TABLE 74 COMPANY AND TYPE OF ANTISENSE PRODUCTS	122
APPENDIX B.....	123
PATENT SUMMARIES	123
AEGERA THERAPEUTICS	123
TABLE 75 ANTISENSE PATENT PORTFOLIO OF AEGERA THERAPEUTICS.....	123
ANGIOGENE INC.	124
TABLE 76 ANTISENSE PATENT PORTFOLIO OF ANGIOGENE.....	124
ANTISENSE PHARMA	124
TABLE 77 ANTISENSE PATENT PORTFOLIO OF ANTISENSE PHARMA	124
AVI BIOPHARMA.....	125
TABLE 78 ANTISENSE PATENT PORTFOLIO OF AVI BIOPHARMA	125
TABLE 78 (CONTINUED).....	126
EPIGENESIS PHARMACEUTICALS	127
TABLE 79 ANTISENSE PATENT PORTFOLIO OF EPIGENESIS	127
GENTA INC.	127
TABLE 80 ANTISENSE PATENT PORTFOLIO OF GENTA.....	127
TABLE 80 (CONTINUED).....	128
HYBRIDON INC.	129
TABLE 81 ANTISENSE PATENT PORTFOLIO OF HYBRIDON	129
TABLE 81 (CONTINUED).....	130
TABLE 81 (CONTINUED).....	131
TABLE 81 (CONTINUED).....	132
TABLE 81 (CONTINUED).....	133
TABLE 81 (CONTINUED).....	134
IMMUSOL INC.	134

<i>TABLE 82 ANTISENSE PATENT PORTFOLIO OF IMMUSOL</i>	135
ISIS PHARMACEUTICALS	135
<i>TABLE 83 ANTISENSE PATENT PORTFOLIO OF ISIS PHARMACEUTICALS</i>	136
<i>TABLE 83 (CONTINUED)</i>	137
<i>TABLE 83 (CONTINUED)</i>	138
<i>TABLE 83 (CONTINUED)</i>	139
<i>TABLE 83 (CONTINUED)</i>	140
<i>TABLE 83 (CONTINUED)</i>	141
<i>TABLE 83 (CONTINUED)</i>	142
<i>TABLE 83 (CONTINUED)</i>	143
<i>TABLE 83 (CONTINUED)</i>	144
<i>TABLE 83 (CONTINUED)</i>	145
<i>TABLE 83 (CONTINUED)</i>	146
<i>TABLE 83 (CONTINUED)</i>	147
<i>TABLE 83 (CONTINUED)</i>	148
<i>TABLE 83 (CONTINUED)</i>	149
<i>TABLE 83 (CONTINUED)</i>	150
<i>TABLE 83 (CONTINUED)</i>	151
<i>TABLE 83 (CONTINUED)</i>	152
<i>TABLE 83 (CONTINUED)</i>	153
<i>TABLE 83 (CONTINUED)</i>	154
<i>TABLE 83 (CONTINUED)</i>	155
<i>TABLE 83 (CONTINUED)</i>	156
<i>TABLE 83 (CONTINUED)</i>	157
<i>TABLE 83 (CONTINUED)</i>	158
LORUS THERAPEUTICS	158
<i>TABLE 84 ANTISENSE PATENT PORTFOLIO OF LORUS THERAPEUTICS</i>	159
METHYLGENE INC.	159
<i>TABLE 85 ANTISENSE PATENT PORTFOLIO OF METHYLGENE</i>	159
<i>TABLE 85 (CONTINUED)</i>	160
RIBOZYME PHARMACEUTICALS	160
<i>TABLE 86 ANTISENSE PATENT PORTFOLIO OF RIBOZYME</i> PHARMACEUTICALS	160
<i>TABLE 86 (CONTINUED)</i>	161
<i>TABLE 86 (CONTINUED)</i>	162
<i>TABLE 86 (CONTINUED)</i>	163
<i>TABLE 86 (CONTINUED)</i>	164